EPAS1 and nonpapillary renal cell carcinoma: Interestingly, exploiting structural differences in PAS-B domain between HIF-1α and HIF-2α, compounds PT2399 and PT2385 have been found to specifically inhibit HIF-2α activity and showed anticancer properties in both cellular and animal renal carcinoma (ccRCC).